Lixia Diao
YOU?
Author Swipe
View article: CyTOF-based profiling of circulating tumor cells predicts aggressiveness and therapy response in SCLC liquid biopsies at a personalized level
CyTOF-based profiling of circulating tumor cells predicts aggressiveness and therapy response in SCLC liquid biopsies at a personalized level Open
Summary Small-cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma characterized by high numbers of circulating tumor cells (CTCs). We applied CyTOF and a 20-marker antibody panel to detect and phenotype CTCs directly in liqui…
View article: Functional, Pharmacogenomic, and Immune Landscapes of Long Non‐Coding RNAs in Cancer
Functional, Pharmacogenomic, and Immune Landscapes of Long Non‐Coding RNAs in Cancer Open
Long non‐coding RNAs (lncRNAs) are emerging as key regulators in cancer, with significant potential as diagnostic, prognostic, and therapeutic targets. Here, this work systematically analyzes lncRNA associations with targeted therapies and…
View article: YAP1 defines an emergent, plastic population of relapsed small cell lung cancer
YAP1 defines an emergent, plastic population of relapsed small cell lung cancer Open
Small cell lung cancer (SCLC) is an aggressive neuroendocrine malignancy characterized by rapid onset of chemoresistance and poor clinical outcomes. Transcriptional heterogeneity among treatment-naïve SCLC tumors underlies four transcripti…
View article: Supplementary Figure S2 from Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial
Supplementary Figure S2 from Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial Open
Supplementary Figure S2. In vitro efficacy of adagrasib in KRASG12C-mutant lung cancer models based on STK11/LKB1 and KEAP1 status.
View article: Supplementary Figure S1 from Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial
Supplementary Figure S1 from Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial Open
Supplementary Figure S1. Clinical outcomes to adagrasib monotherapy according to TP53, ATM and CDKN2A co-mutation status.
View article: Supplementary Figure S8 from Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial
Supplementary Figure S8 from Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial Open
Supplementary Figure S8. STK11/LKB1 and epithelial-mesenchymal transition – EMT – scores in KRASG12C-mutant NSCLC patients treated with adagrasib.
View article: Supplementary Figure S6 from Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial
Supplementary Figure S6 from Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial Open
Supplementary Figure S6. Correlation of NRF2 score and survival to adagrasib monotherapy according to KEAP1 and STK11 co-mutation status.
View article: Supplementary Table S2 from Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial
Supplementary Table S2 from Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial Open
Supplementary Table S2. Clinical characteristics of the KRYSTAL-1 cohort and of the NGS and gene expression profiling evaluable populations.
View article: Supplementary Table S1 from Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial
Supplementary Table S1 from Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial Open
Supplementary Table S1. Adagrasib CRISPR screen data.
View article: Supplementary Figure S7 from Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial
Supplementary Figure S7 from Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial Open
Supplementary Figure S7. Clinical outcomes to adagrasib monotherapy according to NRF2 score and STK11 co-mutation status in KEAP1WT/KRASG12C-mutant NSCLC patients.
View article: Supplementary Figure S5 from Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial
Supplementary Figure S5 from Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial Open
Supplementary Figure S5. NRF2 score is associated with survival upon treatment with adagrasib monotherapy.
View article: Supplementary Figure S4 from Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial
Supplementary Figure S4 from Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial Open
Supplementary Figure S4. NRF2 score in KRASG12C-mutant NSCLC patients treated with adagrasib.
View article: Supplementary Figure S3 from Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial
Supplementary Figure S3 from Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial Open
Supplementary Figure S3. Adagrasib combination drug screens in KRASG12C-mutant lung cancer models.
View article: Supplementary Methods S1 from Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial
Supplementary Methods S1 from Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial Open
Supplementary Methods S1. LKB1/KEAP1 over-expression; Western Blot Analysis; KRAS-GTP Pull-Down Assay.
View article: Data from Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial
Data from Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial Open
Purpose:KRAS inhibitors are revolutionizing the treatment of non–small cell lung cancer (NSCLC), but clinico-genomic determinants of treatment efficacy warrant continued exploration.Experimental Design:Patients with advanced KRASG12C-mutan…
View article: Supplementary Figures S1-S7 from Ancestral Differences in Anticancer Treatment Efficacy and Their Underlying Genomic and Molecular Alterations
Supplementary Figures S1-S7 from Ancestral Differences in Anticancer Treatment Efficacy and Their Underlying Genomic and Molecular Alterations Open
Supplementary Fig. S1. The underrepresentation of Hispanic or Latino populations in clinical trials. (A) The summary of all clinical trials in Clinical Trials obtained on March 24, 2024. (B-C) The populations of Hispanic or Latino, non-His…
View article: Supplementary Tables S1-S7 from Ancestral Differences in Anticancer Treatment Efficacy and Their Underlying Genomic and Molecular Alterations
Supplementary Tables S1-S7 from Ancestral Differences in Anticancer Treatment Efficacy and Their Underlying Genomic and Molecular Alterations Open
Supplementary Table S1. The outcomes of all 46 clinical trials with racial comparisons. Supplementary Table S2. The list of clinically actionable genes. Supplementary Table S3. Summary of TCGA cancer types, patient samples and data types s…
View article: Data from Ancestral Differences in Anticancer Treatment Efficacy and Their Underlying Genomic and Molecular Alterations
Data from Ancestral Differences in Anticancer Treatment Efficacy and Their Underlying Genomic and Molecular Alterations Open
Systematic multiomic analysis has revealed ancestry-dependent molecular alterations, but their impact on the efficacy of anticancer treatment is yet largely unknown. In this study, we analyzed clinical trials from ClinicalTrials.gov and fo…
View article: Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial
Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial Open
Purpose: KRAS inhibitors are revolutionizing the treatment of non–small cell lung cancer (NSCLC), but clinico-genomic determinants of treatment efficacy warrant continued exploration. Experimental Design: Patients with advanced KRASG12C-mu…
View article: Comprehensive characterization of the transcriptional landscape in Alzheimer’s disease (AD) brains
Comprehensive characterization of the transcriptional landscape in Alzheimer’s disease (AD) brains Open
Alzheimer’s disease (AD) is the leading dementia among the elderly with complex origins. Despite extensive investigation into the AD-associated protein-coding genes, the involvement of noncoding RNAs (ncRNAs) and posttranscriptional modifi…
View article: Ancestral Differences in Anticancer Treatment Efficacy and Their Underlying Genomic and Molecular Alterations
Ancestral Differences in Anticancer Treatment Efficacy and Their Underlying Genomic and Molecular Alterations Open
Systematic multiomic analysis has revealed ancestry-dependent molecular alterations, but their impact on the efficacy of anticancer treatment is yet largely unknown. In this study, we analyzed clinical trials from ClinicalTrials.gov and fo…
View article: Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms
Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms Open
Delta-like Ligand 3 (DLL3) targeting therapies are promising in small cell lung cancer (SCLC) treatment. However, DLL3 expression in SCLC and other neuroendocrine neoplasms (NEN) is heterogeneous and not well characterized. We describe the…
View article: Supplementary Figure S6 from YAP1 Status Defines Two Intrinsic Subtypes of LCNEC with Distinct Molecular Features and Therapeutic Vulnerabilities
Supplementary Figure S6 from YAP1 Status Defines Two Intrinsic Subtypes of LCNEC with Distinct Molecular Features and Therapeutic Vulnerabilities Open
Supplementary Figure S6. Drug response differences in YAP1-high and -low LCNEC preclinical models.
View article: Supplementary Figure S7 from YAP1 Status Defines Two Intrinsic Subtypes of LCNEC with Distinct Molecular Features and Therapeutic Vulnerabilities
Supplementary Figure S7 from YAP1 Status Defines Two Intrinsic Subtypes of LCNEC with Distinct Molecular Features and Therapeutic Vulnerabilities Open
Supplementary Figure S7. Surfaceome targets in LCNEC.